What is the 13F Pro Quality Score for CCCC?

13F Pro ranks C4 Therapeutics, Inc. (CCCC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CCCC's current score at https://13fpro.ai/research/CCCC (free sign-up required for the full ranking).

Where does 13F Pro source CCCC data?

All C4 Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. C4 Therapeutics, Inc. files with the SEC under CIK 1662579. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CCCC in?

C4 Therapeutics, Inc. (CCCC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CCCC research updated on 13F Pro?

CCCC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

C4 Therapeutics, Inc.(CCCC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1662579 CCCC stock profile & AI dashboard →

13F Pro Quality Score

6.5/100

Rank #2,841 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.1/100

Profitability

4.2/100

Balance Sheet

7.3/100

Earnings Quality

30.0/100

Free Cash Flow

4.1/100

Institutional Flow

9.4/100

Revenue Scale

7.6/100

Dilution Risk

4.6/100

CCCC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for C4 Therapeutics, Inc. (CCCC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CCCC at 6.5/100 on a 32-signal composite quality model, placing it at rank #2,841 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (3.1) and free cash flow (4.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), C4 Therapeutics, Inc. reports quarterly revenue of $6.2M, net income of $-25.1M, free cash flow of $-30.0M. Top institutional holders of CCCC by reported 13-F value include MORGAN STANLEY, RA CAPITAL MANAGEMENT, L.P., Bain Capital Life Sciences Investors,, based on the most recent SEC filings. CCCC trades on the Nasdaq exchange and files with the SEC under CIK 1662579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for C4 Therapeutics, Inc. directly from SEC EDGAR. C4 Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 65 since 2023, currently 6.5 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about C4 Therapeutics, Inc.

Quirks, history, and lore behind CCCC — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on targeted protein degradation.
2
The Numbers
A pre-revenue biotech burning through cash on R&D — market cap has hovered in the low hundreds of millions — classic small-cap drug discovery territory.
3
The History
Founded around 2019 and spun out of the orbit of Novartis, which backed the company early and helped seed its science platform.
4
The Secret
Its core trick is using the cell's own garbage-disposal machinery — the proteasome — to destroy disease-causing proteins that conventional drugs simply can't touch, a field called targeted protein degradation.
5
The Lore
The company's platform is built around a next-generation approach called monovalent degraders, designed to be cleaner and more drug-like than the bulky PROTAC molecules that put this field on the map.
6
The Giveaway
Its ticker is literally four C's in a row — a nod to the C4 in its name, which stands for the chemistry of Cereblon-mediated protein degradation.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$6.2M

Net Income

Q1 2026

$-25.1M

Free Cash Flow

Q1 2026

$-30.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+73.2% YoY

$35.9MFY 2025

FY21 $45.8MFY22 $31.1MFY23 $20.8MFY25 $35.9M

Net Income

+20.8% YoY

$-105.0MFY 2025

FY21 $-83.9MFY22 $-128.2MFY23 $-132.5MFY25 $-105.0M

Operating Income

+17.1% YoY

$-115.2MFY 2025

FY21 $-82.1MFY22 $-129.5MFY23 $-139.0MFY25 $-115.2M

EPS (Diluted)

+52.4% YoY

$-1.27FY 2025

FY21 $-1.82FY22 $-2.62FY23 $-2.67FY25 $-1.27

Total Assets

-4.6% YoY

$359.1MFY 2025

FY21 $506.8MFY22 $430.8MFY23 $376.5MFY25 $359.1M

Total Debt

—FY 2025

FY21 $10.8MFY22 $13.8MFY23 $0.00FY25 —

Op. Cash Flow

+7.6% YoY

$-98.7MFY 2025

FY21 $-87.0MFY22 $-105.9MFY23 $-106.8MFY25 $-98.7M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$35.9M +73.2%	$20.8M -33.3%	$31.1M -32.1%	$45.8M	—	—
Net Income	$-105.0M +20.8%	$-132.5M -3.4%	$-128.2M -52.8%	$-83.9M -26.5%	$-66.3M -94.5%	$-34.1M
Operating Income	$-115.2M +17.1%	$-139.0M -7.3%	$-129.5M -57.7%	$-82.1M -35.9%	$-60.4M -70.5%	$-35.5M
EPS (Diluted)	$-1.27 +52.4%	$-2.67 -1.9%	$-2.62 -44.0%	$-1.82	—	—
Total Assets	$359.1M -4.6%	$376.5M -12.6%	$430.8M -15.0%	$506.8M +26.6%	$400.1M +238.4%	$118.3M
Total Debt	—	$0.00 -100.0%	$13.8M +27.9%	$10.8M +7.1%	$10.1M	—
Operating Cash Flow	$-98.7M +7.6%	$-106.8M -0.8%	$-105.9M -21.8%	$-87.0M -29.3%	$-67.2M -220.9%	$55.6M

AI Insight: CCCC Financial Trends

C4 Therapeutics remains unprofitable with minimal revenue; equity base volatile and cash burn persistent across all recent quarters.

• Revenue has contracted from $30M in Q3 2024 to $6–11M range in 2025–Q1 2026, reflecting 70–80% decline.

• Net losses narrowed from $71M in Q3 2024 to $20–32M in recent quarters, but company remains deeply unprofitable.

• Operating cash flow consistently negative: $-47M to $-12M per quarter; Q2 2025 showed least burn at $-12M.

⚠ Equity oscillated sharply: fell from $243M (Q3 2024) to $154M (Q3 2025), then spiked to $257M (Q4 2025), settling at $234M (Q1 2026).

⚠ Continued quarterly net losses and negative operating cash flow eroding equity base despite attempted stabilization.

AI Insight: CCCC Ratio Trends

C4 Therapeutics remains unprofitable across all return metrics, with Q4 2025 showing a spike in losses but Q1 2026 stabilizing slightly versus the TTM average.

• ROA improved from -48.5% in Q3 2025 to -22.8% in Q4 2025, then deteriorated to -30.6% in Q1 2026—volatile trajectory amid ongoing losses.

• ROIC ranged from -36.1% (Q4 2025) to -89.1% (Q3 2025); Q1 2026 at -47.4% sits between recent extremes but remains deeply negative.

• Leverage remains minimal: D/E was 0.05 in Q4 2023 and 0.04 in Q3 2024; near-zero debt cushions balance sheet risk.

⚠ Persistent unprofitability and negative returns on equity, assets, and invested capital indicate no clear path to profitability yet disclosed.

⚠ Q4 2025 NPM spiked to -186.0%—worst on record—before Q1 2026 data gap; magnitude and cause warrant scrutiny.

Get alerted when CCCC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for C4 Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CCCC

MORGAN STANLEY
$23.9M9,072,400 sh
RA CAPITAL MANAGEMENT, L.P.
$21.0M8,000,000 sh
Bain Capital Life Sciences Investors, LLC
$18.9M7,171,910 sh
Lynx1 Capital Management LP
$18.4M6,998,902 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.2M3,861,852 sh
Soleus Capital Management, L.P.
$10.0M3,803,942 sh
TWO SIGMA INVESTMENTS, LP
$8.0M3,035,634 sh
WASATCH ADVISORS LP
$7.8M2,961,761 sh
CITADEL ADVISORS LLC
$6.6M2,511,015 sh
RENAISSANCE TECHNOLOGIES LLC
$6.5M2,461,815 sh

Fund	Value	Shares
MORGAN STANLEY	$23.9M	9,072,400
RA CAPITAL MANAGEMENT, L.P.	$21.0M	8,000,000
Bain Capital Life Sciences Investors, LLC	$18.9M	7,171,910
Lynx1 Capital Management LP	$18.4M	6,998,902
VANGUARD CAPITAL MANAGEMENT LLC	$10.2M	3,861,852
Soleus Capital Management, L.P.	$10.0M	3,803,942
TWO SIGMA INVESTMENTS, LP	$8.0M	3,035,634
WASATCH ADVISORS LP	$7.8M	2,961,761
CITADEL ADVISORS LLC	$6.6M	2,511,015
RENAISSANCE TECHNOLOGIES LLC	$6.5M	2,461,815

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CCCC on your watchlist

Track score changes the day C4 Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CCCC a good stock to buy?

13F Pro's AI-powered analysis of C4 Therapeutics, Inc. (CCCC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CCCC are available on the CCCC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CCCC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CCCC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of C4 Therapeutics, Inc.'s investment landscape.